

May 25, 2019

**To,
Dy. General Manager
Department of Corporate Services,
BSE Ltd.,
P. J. Towers, Dalal Street,
Fort, Mumbai – 400 001.**

**To,
The Manager – Listing,
The National Stock Exchange of India Ltd.,
Plot No. C/1, G Block,
Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051.**

Ref: Scrip Code: 532296

Ref: Scrip Name: GLENMARK

Dear Sirs,

This is to inform you that the meeting of the Board of Directors of the Company scheduled on Wednesday, 29 May, 2019, will consider, apart from audited financial result and declaration of dividend, also consider the proposal to enable raising of funds through issue of debt securities whether denominated in Indian Rupee and/or foreign currency(ies) either by way of a public issue or by way of a private placement in accordance with the provisions of the applicable law, subject to necessary approvals, if any. Proceeds from these debt securities issuance will be used mainly to refinance existing debt.

Please treat this as the intimation required under Regulation 29(1) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

The above is for your information.

Thanking you

Yours faithfully,
For Glenmark Pharmaceuticals Limited

**Harish Kuber
Company Secretary Compliance Officer**

Tel: 4018 9999 / 4018 9879
Fax: 4018 9986 (Legal & Secretarial Dept.)

Glenmark Pharmaceuticals Ltd.

Glenmark House, B D Sawant Marg, Andheri (E), Mumbai 400 099
T: 91 22 4018 9999 F: 91 22 4018 9988 CIN No: L24299MH1977PLC019982 W: www.glenmarkpharma.com
Registered office: B/2, Mahalaxmi Chambers, 22 Bhulabhai Desai Road, Mumbai 400 026 E: complianceofficer@glenmarkpharma.com